Ad
related to: journal of experimental pharmacology vol 16
Search results
Results From The WOW.Com Content Network
Concurrently, he held editorial positions including, Editor for Cellular Pharmacology, and Editor-in-Chief of Journal of Pharmacology and Experimental Therapeutics. [7] Tew has been the Editor (USA) of Biomedicine & Pharmacotherapy since 2002 [6] and Serial Editor for Advances in Cancer Research since 2011. [9]
The Journal of Pharmacology and Experimental Therapeutics is a monthly peer-reviewed scientific journal covering pharmacology. It was established in 1909 and is published by Elsevier on behalf of the American Society for Pharmacology and Experimental Therapeutics .
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
Among Kuhl's most widely cited publications is his 2005 literature review in the journal Climacteric, Pharmacology of Estrogens and Progestogens: Influence of Different Routes of Administration. [ 3 ] [ 4 ] He has published several articles interpreting the findings of the Women's Health Initiative (WHI) study.
Scott A. Waldman is an MD and biomedical scientist at Sidney Kimmel Medical College of Thomas Jefferson University, where he is the Samuel M.V. Hamilton Professor of Medicine, and also tenured professor and chair of the Department of Pharmacology & Experimental Therapeutics.
JNJ-7777120 was a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H 4 receptor. [1]
SAGE-324, also known as BIIB124, is an experimental drug. It is a neurosteroid that works as a GABA A receptor positive allosteric modulator. [1] [2] [3] SAGE-324 was being developed by Biogen for the treatment of essential tremor. [4] Its development was discontinued in 2024 due to lack of efficacy in Phase 2 clinical trials. [5]
Language links are at the top of the page across from the title.